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Mutations of the p53 gene are detected frequently in oesophageal dysplasia and cancer. It is unclear whether Lugol-unstained lesions
(LULs) with non-dysplastic epithelium (NDE) are precursors of oesophageal squamous cell carcinoma (ESCC). To study the genetic
alterations of NDE in the multistep process of oesophageal carcinogenesis, we determined the relationship between p53 mutations
and LULs-NDE. Videoendoscopy with Lugol staining was performed prospectively in 542 oesophageal cancer-free subjects. Lugol-
unstained lesions were detected in 103 subjects (19%). A total of 255 samples, including 152 LULs (NDE, 137; dysplasia, 15) and 103
paired samples of normal staining epithelium, were obtained from 103 subjects. After extraction of DNA and polymerase chain
reaction analysis, direct sequencing method was applied to detect mutations of the p53 gene. The p53 mutation was detected in five
of 137 samples with LULs-NDE (4%) and in five of 15 samples with dysplasia (33%). A hotspot mutation was found in 20% of LULs-
NDE with p53 mutation and in 40% of dysplasia with p53 mutation. In contrast, no p53 mutations were found in 103 paired NDE
samples with normal Lugol staining. In biopsy samples from oesophageal cancer-free individuals, the p53 missense mutations
containing a hotspot mutation were found in NDE, which was identified as an LUL. These findings suggest that some LULs-NDE may
represent the earliest state of oesophageal squamous cell carcinoma in Japanese individuals.
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Oesophageal squamous cell carcinoma (ESCC) is one of the most
common carcinoma worldwide, with marked variation in its
incidence rate among different countries, distinct geographic
areas, and different ethnic groups (Parkin et al, 1988). Among
oesophageal cancers in Japanese patients, 95% are squamous cell
carcinomas (Registration Committee for Esophageal Cancer). In
Western countries and Japan, heavy cigarette smoking and alcohol
intake are the risk factors, whereas in the developing countries,
exposure to dietary carcinogens and nutritional deficiencies are
believed to be the major aetiologic factors (Yang, 1980; Von
Rensburg, 1981; Parkin et al, 1988; Yokoyama et al, 1995).
However, results from previous studies suggest that malignant
transformation of human oesophageal epithelium is a multistage
progressive process (Yang, 1980; Yang and Qiu, 1987; Qiu and
Yang, 1988; Wang et al, 1990; Bennett et al, 1992; Wang et al, 1993;
Greenblatt et al, 1994).
Characterisation of human oesophageal precancerous lesions at
the molecular level is of critical importance to our understanding
of the aetiology of ESCC and to the identification of useful
biomarkers for prevention studies of that disease. Mutation
analyses among high-risk Chinese populations have demonstrated
that p53 gene mutations occur at an early stage of oesophageal
carcinogenesis, both in the setting of basal cell hyperplasia (BCH)
and in dysplastic lesions (Bennett et al, 1992; Wang et al, 1993; Gao
et al, 1994; Jaskiewicz and De Groot, 1994; Parenti et al, 1995). An
early indicator of abnormality in individuals predisposed to ESCC
is an increased proliferation of the oesophageal epithelial cells,
morphologically manifested as BCH, dysplasia, and cancer in situ.
Most of these lesions could be considered as precancerous lesions
because of the presence of p53 mutations (Yang, 1980; Yang and
Qiu, 1987; Qiu and Yang, 1988; Wang et al, 1990; Mandard et al,
2000). But it is under debate whether BCH is a precancerous lesion
for ESCC or not, as no hotspot mutations of the p53 gene were
found in BCH samples (Shi et al, 1999).
Although endoscopic detection for early ESCC is extremely
important because of excellent 5-year survival rate (Yoshinaka
et al, 1991; Kumagai et al, 1993), two-thirds of oesophageal
intraepithelial carcinomas have been overlooked by conventional
endoscopy alone (Sugimachi et al, 1989). A simple technique of
spraying Lugol solution in the oesophagus is highly sensitive for
identifying dysplasia and intraepithelial carcinoma (Mori et al,
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s1993; Meyer et al, 1997; Dawsey et al, 1998). According to the
Lugol staining pattern, completely ‘unstained’ areas were found in
approximately 90% of high-grade dysplasia and carcinoma,
whereas approximately 90% of staining areas, which were less
intensely stained than normally stained epithelium, were non-
dysplastic lesions and the remaining 10% were dysplasia (Mori
et al, 1993). Therefore, Lugol-unstained lesions (LULs) are
detectable not only in dysplasias and carcinomas but also in
non-dysplastic areas, for example with oesophagitis, or in the
setting of Barrett’s oesophagus (Sugimachi et al, 1989; Dawsey
et al, 1998). In contrast, Lugol staining methods were not used in
most studies regarding p53 mutational status in oesophageal
precancerous lesions such as dysplasia, BCH, and esophagitis
(Yang and Qiu, 1987; Qiu and Yang, 1988; Wang et al, 1990;
Bennett et al, 1992; Wang et al, 1993; Gao et al, 1994; Greenblatt
et al, 1994; Jaskiewicz and De Groot, 1994; Parenti et al, 1995; Shi
et al, 1999; Mandard et al, 2000).
Resected specimens from cancer patients were used in the
analysis of the p53 mutations in the previous studies (Yang, 1980;
Yang and Qiu, 1987; Qiu and Yang, 1988; Wang et al, 1990; Shi
et al, 1999; Mandard et al, 2000). Little information is available
regarding the p53 mutational status in the Lugol-unstained lesions
with non-dysplastic epithelium (LULs-NDE) of oesophageal
cancer-free subjects. To determine the genetic alterations in the
early stage of oesophageal carcinogenesis, oesophageal cancer-free
subjects should be selected. Endoscopic detection of oesophageal
precancerous lesions and molecular diagnosis is of clinical
importance to identify high-risk patients and to prevent the
development of ESCC. We carried out a prospective study of the
p53 mutational status of both LULs-NDE and paired samples of
normal Lugol staining areas from endoscopic biopsy samples
obtained after spraying the oesophagus with Lugol solution.
MATERIALS AND METHODS
Study design
To investigate whether LULs-NDE were related to the carcino-
genesis of oesophageal squamous epithelium or not, the p53
mutational status in LULs-NDE was analysed prospectively.
Secondary end points were to elucidate whether BCH is related
to oesophageal carcinogenesis through the p53 mutational status
and examine malignant potential in multiple LULs. Recruited
subjects were composed of oesophageal cancer-free individuals
who visited our hospital for a health checkup between April 1999
and March 2001. Subjects were recruited on the basis of the
following criteria: male and female individuals, age in the range
of 20–80 years, the subjects performance status being ‘zero’
according to Eastern Cooperative Oncology Group (ECOG), and
the subjects with no symptoms of dysphagia, abdominal pain,
chest and/or back pain, or vomiting were eligible. As LULs can be
caused by reflux oesophagitis, subjects with heartburn and those
receiving proton pump inhibitor therapy were excluded. Subjects
who had active malignant disease, and who had undergone
oesophagectomy or chemoradiotherapy for ESCC, were excluded.
After endoscopic observation, subjects who had oesophageal
varices, Barrett’s oesophagus, or reflux oesophagitis were also
excluded. Although heavy cigarette smoking and alcohol intake
are the major risk factors of ESCC, whether the oesophageal
precancerous lesions are caused by such daily consumption or not
is uncertain. Therefore, the subjects were not selected based on
risk factors such as smoking and alcohol drinking. Participants
were interviewed using structured questionnaires, which included
queries about smoking and drinking status after recruitment. All
subjects gave informed consent for participation in the study. The
study protocol was approved by the Human Ethics Review
Committee of Showa University School of Medicine.
Patient population
A total of 599 subjects were recruited: 542 subjects matched the
recruitment criteria and 42 subjects were excluded from the study.
The reasons for exclusion were symptom-free reflux oesophagitis
in 15 subjects, Barrett’s oesophagus in five subjects, gastric
carcinoma in one subject, and rejection to the study in 21 subjects.
The mean age was 61 years, ranging from 20 to 80 years, and the
male to female ratio was 274/268. Of the 542 subjects, 157 (29%)
and 130 (24%) had daily consumption of cigarette and alcohol,
respectively.
Endoscopic examination
Videoendoscopy (Q240, Olympus, Tokyo, Japan) following Lugol
solution spraying was performed on all oesophageal cancer-free
subjects who matched the recruitment criteria. After ordinary
endoscopic observation, 5–10ml of 2.0% glycerin-free Lugol’s
iodine solution, which was a brown liquid consisting of 2.0g
potassium iodine and 4.0g iodine in 100ml distilled water, was
sprayed from the gastroesophageal junction to the upper
oesophagus using a plastic spray catheter (washing tube PW-5L;
Olympus, Tokyo, Japan) passed through the biopsy channel of
the endoscope. The whole oesophagus was observed again and
epithelial areas were categorised as unstained, normally stained, or
overstained. We defined LULs as those areas either staining less
intensely than normally stained epithelium or completely un-
stained (Figure 1A–C); this group of lesions included carcinoma,
dysplasia, and oesophagitis. When 10 and more than 10 LULs were
detected in one endoscopic view, we defined them as multiple
LULs (Figure 1D). Biopsies were taken under endoscopic guidance
for LULs and paired normal Lugol staining background epi-
thelium. The background epithelium specimens were obtained
1–5cm away from LULs. We confirmed that samples were
correctly taken from LULs during endoscopic observation.
Histologic diagnosis among normal epithelium, oesophagitis,
BCH, dysplasia, and carcinoma was made according to previously
described definitions (Dawsey et al, 1994). Histologic features were
evaluated by a pathologist in our hospital.
DNA extraction
Ten 2-mm-thick sections were obtained from each archival block
of formalin-fixed and paraffin-embedded dysplastic and non-
dysplastic tissue. One section of each block was stained with
haematoxylin and eosin. The percentage of neoplastic cells was
estimated by light microscopic evaluation, and the samples
containing a minimum of 60% dysplastic cells were chosen. DNA
samples were extracted by the ethanol/xylene method from the
remaining nine sections (Goelz et al, 1985).
Analysis of the p53 gene
Specimens were mixed with 50ml of digestion buffer (0.04%
proteinase K, 10mM Tris-HCl at pH 8.0, 1mM EDTA, and 1%
Tween 20) and incubated at 371C for 18h. The DNA fragments
were analysed for mutations in p53 exons 5, 6, 7, and 8, as
described in our previous report (Makino et al, 2000). Primers
used for polymerase chain reaction (PCR) amplification of the p53
gene were as follows: for exon 5, 50-TTCACTTGTGCCCTGATTTC-30
and 50-CTCTCCAGCCCCAGCTGCTC-30; for exon 6, 50-ATTCCT-
CACTGATTGCTCC-30 and 50-TCCTCCCAGAGACCCCAGTT-30;
for exon 7, 50-ACAGGTCCTCCCCAAGGCGCA–30 and 50-TGTGCA
GGGTGGCAAGTGGCT-30; for exon 8, 50-GTAGGACCTGATTTCC
TTACTGCC-30 and 50-CTTGGTCTCCTCCACCGCTTCTTG-30.
Polymerase chain reaction conditions were set as described in
our report (Makino et al, 2000). The PCR products were purified
and directly sequenced using a 3100 sequencing machine (Applied
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sBiosystems, Foster City, CA, USA). Peak patterns were analysed
using Sequencing Analysis Software (Applied Biosystems, Foster
City, CA, USA), and mutations and amino-acid changes were
identified (Figure 2). To ensure reproducibility of our data, direct
sequencing was performed at least twice in DNA samples.
Statistical analysis
As LULs were found in approximately 20% of 1000 patients
undergoing routine endoscopy in our previous experience, sample
size was estimated to be 500 patients to collect at least 100 patients
with LULs. To avoid bias, the data regarding the detection of p53
mutation in LULs and their paired normal Lugol staining areas
were re-identified for genetic and clinicopathologic analyses. These
data were then matched after the genetic and clinicopathologic
analyses were completed. The significance of differences between
the two groups was assessed by the w
2 test or Wilcoxon rank-sum
test. P-value of less than 0.05 was considered significant.
RESULTS
Characteristics of subjects
Out of 542 subjects, LULs were found in 103 (19%).The mean age
was 62 years, ranging from 25 to 80 years, and the male to female
ratio was 63/50. Of the 103 subjects, 35 (34%) and 31 (30%) had a
daily habit of cigarette smoking and alcohol drinking, respectively.
No significant difference in the frequency of daily cigarette
smoking (P¼0.213) or alcohol (P¼0.107) consumption was seen
between the subjects with LULs and those without.
Histologic and clinicopathologic findings
The samples of LULs consisted of 137 NDE and 15 dysplastic
samples, whereas no dysplastic samples were detected in the
normal Lugol staining samples (Table 1). Whereas the histologic
finding in all samples of LULs-NDE was oesophagitis, 78% of the
103 normal Lugol staining epithelium samples were oesophagitis
(Po0.0001). The histologic grade of dysplastic samples was
AB
D C
Figure 1 (A) Endoscopic findings of a Lugol-unstained lesion. This lesion was completely unstained. The lesion was oval and 4mm in diameter. (B)
Endoscopic findings of a Lugol-unstained lesion. This lesion was completely unstained. The lesion was irregular in shape and 6mm in diameter. (C)
Endoscopic findings of normal Lugol staining epithelium without a Lugol-unstained lesion. (D) Endoscopic findings of multiple Lugol-unstained lesions. Many
irregular lesions that were stained less intensely than normal Lugol staining epithelium were located in one endoscopic view.
CGC
wt mut
CAC
Figure 2 Mutation of the p53 gene at codon 175 in exon 5 was shown
in electropherograms. Base changed from CGC to CAC (black arrow). wt,
wild type; mut, mutation.
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slow-grade in nine of 15 (60%) samples and high-grade in six (40%)
samples.
The clinicopathologic findings of LULs-NDE and dysplasia are
shown in Table 2. Most LULs-NDE and dysplasia also were located
in the middle third of the thoracic oesophagus, as most invasive
ESCCs were located in the same portion (Registration Committee
for Esophageal Cancer). The characteristics of LULs-NDE were
minute size (o5mm in diameter), oval shape, and location in the
middle third of the oesophagus.
Mutation of the p53 gene
p53 mutation was detected in five of the 137 LULs-NDE samples,
whereas no p53 mutations were found in normal Lugol staining
epithelium samples (Table 2). The mutations of the p53 gene in
LULs-NDE were one in exon 6, three in exon 7, and one in exon 8,
and all were missense mutations (Table 3). A ‘hotspot’ mutation at
codon 273 was found in one of the five LULs-NDE. A p53 mutation
was found in three of nine subjects (33%) with low-grade dysplasia
and two of six subjects (33%) with high-grade dysplasia. The
mutations of the p53 gene in dysplastic lesions were three in exon
5 and two in exon 6, and four were missense mutations and one
was a nonsense mutation resulting in insertion of a stop codon. A
hotspot mutation at codon 175 was found in two of five dysplasia
samples and these two samples were low-grade dysplasia.
In contrast, 22 (16%) of 137 LULs-NDE showed squamous
atypia (Table 4). p53 mutation was found in one (4.5%) of 22
LULs-NDE with squamous atypia (Figure 3A), and in four (3.5%)
of 115 LULs-NDE without squamous atypia (Figure 3B and
Table 4). Approximately 80% of the normal Lugol staining
epithelium samples were oesophagitis, whereas no squamous
atypia was found in normal epithelium samples.
Basal cell hyperplasia was present in 2% of LUL samples and
2% of normal Lugol staining epithelium samples alone (Table 1).
Notably, p53 mutations were not found in both LULs-NDE and
normal Lugol staining epithelium samples with BCH (Table 4).
Multiple LULs
A single or few LULs were detected in 98 (95%) subjects and
multiple LULs were found in five (5%) subjects (Table 5). Although
multiple LULs were found in only five (0.9%) of the 542 subjects,
three of the five subjects with multiple LULs (60%) had dysplasia
(P¼0.003; Table 5).
No significant difference was seen in the occurrence of p53
mutations between subjects with single or few LULs and multiple
LULs (Table 5). Although the same mutation in exon 6 at (codon
218) was found in both dysplasia and LULs-NDE in case 2 with
multiple LULs-NDE (Table 3), the two lesions were independent
and were not contiguous. One lesion was located in the middle
oesophagus, with dysplasia of 6-mm diameter area; the other was
located in the lower oesophagus, with LUL-NDE of 4-mm diameter
area.
Table 1 Histologic findings of biopsy samples from 103 oesophageal
cancer-free patients
Lugol-unstained
lesions
Normal Lugol
staining epithelium P-value
Number of samples 152 103
Histologic findings
Dysplasia 15 —
Oesophagitis 137 80 o0.0001
Normal epithelium — 23
Basal cell hyperplasia
Present 3 2 0.986
Absent 149 101
Table 2 Clinicopathologic characteristics and presence of p53 mutation
of LUL-NDE and dysplasia
LUL-NDE (n¼137) Dysplasia (n¼15) P-value
Mean size (mm) 4 9 0.032
Range (mm) 1–6 5–20
Shape of LUL
Oval 108 5 o0.0001
Irregular 29 10
Location
Upper third 19 1 0.441
Middle third 90 9
Lower third 28 5
P53 mutation
Present 5 5 o0.0001
Absent 132 10
Hotspot mutation (10 samples with p53 mutation)
Present 1 2 0.490
Absent 4 3
LUL-NDE¼Lugol-unstained lesion with non-dysplastic epithelium; location¼loca-
tion of the oesophagus.
Table 3 Mutation of the p53 gene in patients with Lugol-unstained lesions
Case Age/sex Histology Size (mm) p53 Ex Codon BC AAC
1 52/M itis 3 P 7 242 TGC-TCC K-S
2 53/M sev, dys. 6 P 6 218 GTG-GAG V-E
itis 4 P 6 218 GTG-GAG V-E
itis 3 A
3 78/M mod, dys. 0 P 6 192 CAG-TAG *
4 71/M mild, dys. 8 P 5 175 CGC-CAC R-H
5 53/F mild, dys. 6 P 5 175 CGC-GGC R-G
6 63/M sev, dys. 13 P 5 184 GAT-AAT D-N
7 68/F itis 3 P 7 241 TCC-TAC S-Y
8 75/M itis 4 P 8 273 CGT-TGT R-C
itis 2 A
9 60/F itis 4 P 7 239 AAC-GAC N-D
itis 5 A
itis 3 A
itis¼oesophagitis; dys, dysplasia; sev¼severely; mod¼moderately; P¼presence of a p53 mutation; A¼absence of a p53 mutation; EX¼exon; BC¼base change;
AAC¼amino-acid change; *¼stop codon.
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sDISCUSSION
This study is aimed to evaluate whether LULs-NDE are related to
the carcinogenesis of oesophageal squamous epithelium or not,
and p53 mutational status in LULs-NDE is analysed on the basis of
molecular events in the progressive process of carcinoma. As p53
mutation is a well-known sequence in dysplasia and carcinoma,
this biomarker was determined to identify the precancerous
lesions in the study. The unique observation in this prospective
study is that missense mutations of the p53 gene were found in
LULs-NDE, although no p53 mutations were found in paired
normally Lugol-stained non-dysplastic epithelium in subjects with
LULs-NDE. The results strongly suggest that some of the LULs-
NDE can progress to dysplastic lesions through p53 alterations and
support the hypothesis that some of ‘Lugol-unstained non-
dysplastic areas’ in Japanese individuals without reflux esophagitis
play an important role in oesophageal carcinogenesis.
Mutations of the p53 tumour suppressor gene are the most
common genetic abnormalities in solid human cancers (Nigro
et al, 1989; Hollstein et al, 1990; Lane, 1992; Vogelstein et al, 2000;
Vousden and Lu, 2002; Oliver et al, 2004). Missense mutations are
found in 78% of the 6177 somatic p53 mutations in exons 5–8
(Hussain and Harris, 1999), suggesting a correlation between the
degree of evolutionary diversity and the structural or functional
importance of individual amino-acid residues (Greenblatt et al,
1994). The change of protein structure or function caused by the
individual amino-acid residues in LULs-NDE might be early
molecular events in carcinogenesis. In contrast, p53 gene
mutations have been proposed to be concentrated in six hotspots
(Hainaut et al, 1997; Hussain and Harris, 1999; Vikhanskaya et al,
2005). Based on the updated p53 Gene Mutation Database
containing 5961 mutations, codons 175, 245, 248, 249, 273, and
282 have been identified as mutation hotspots in human cancers,
and the incidence of the hotspot mutations is specific molecular
alterations in solid human cancers (Hainaut et al, 1997). A hotspot
can identify a relationship between the mutation, protein structure
and function, and carcinogenesis (Hsu et al, 1991; Cho et al, 1994;
Greenblatt et al, 1994; Tornaletti and Pfeifer, 1994). Furthermore,
hotspot mutations in carcinomas represent protein alterations
that provide a selective growth advantage to the cell, and missense
mutations at six hotspots account for 25–30% of the mutations
(Greenblatt et al, 1994; Hainaut et al, 1997; Hussain and Harris,
1999; Ito et al, 2000). Therefore, protein alterations that provide a
selective growth advantage to the cell would have already occurred
in cells of LULs-NDE before histologic transformation into
dysplastic cells. Mutations at codon 175 and 273 have been shown
to have transforming frequencies that are 22- and eight-fold,
respectively, the basal level of wild-type p53 protein (Zambetti and
Levine, 1993). From our results, the LUL-NDE or low-grade
dysplasia containing mutations with high transforming activities,
such as codon 175 and 273 mutations, might have growth
advantages favouring progression to invasive ESCC with the
acquisition of other genetic changes, and may acquire malignant
potential before morphologically manifested cell proliferation at an
early molecular level of carcinogenesis.
One group has proposed that BCH is an early indicator of
oesophageal carcinogenesis (Yang, 1980; Yang and Qiu, 1987; Qiu
and Yang, 1988; Wang et al, 1990). Wang et al (1996) reported that
BCH can be found in 69% of biopsy samples in symptom-free
patients and that p53 mutations can be found in BCH and
dysplastic samples, whereas no hotspot mutations are contained in
these mutations (Shi et al, 1999). We also identified the histologic
findings of BCH in LULs-NDE and the paired normal Lugol
staining area according to histologic criteria used in the Chinese
group (Dawsey et al, 1994), whereas prevalence of BCH was low
in our Japanese subjects and no p53 mutations were found. We
do not believe that the role of BCH is related to oesophageal
carcinogenesis in the Japanese population. In contrast, we did not
suggest that the daily cigarette or alcohol consumption was
directly related to the occurrence of LULs-NDE in this study
despite high risk factors in patients with ESCC.
Using Lugol solution spraying methods, as the normal
squamous epithelium contains glycogen that interacts with the
Table 4 Relationship between presence of p53 mutation and BCH or
squamous atypia in 137 LULs-NDE
p53 mutation p53 mutation
Present (n¼5) Absent (n¼132) P-value
Squamous atypia
Present (n¼22) 1 21 0.807
Absent (n¼115) 4 111
BCH
Present (n¼3) 0 3 0.733
Absent (n¼134) 5 129
LULs-NDE¼Lugol-unstained lesions with non-dysplastic epithelium; BCH¼basal
cell hyperplasia.
A
B
Figure 3 (A) Histologic findings of squamous atypia in a Lugol-unstained
lesion with p53 mutation. The region with squamous atypia was a small
portion in contact with the basal cell layer. In the region, the nucleus was
slightly enlarged, whereas pleomorphism and hyperchromasia were not
seen. According to histological criteria of the Chinese group, the findings
of slightly mononuclear enlargement having neither pleomorphism
nor hyperchromasia were insufficient for diagnosis of dysplasia, and was
decided as inflammation containing atypia. (B) Histologic findings of no
squamous atypia in a Lugol-unstained lesion with p53 mutation. Of the five
Lugol-unstained lesions with non-dysplastic epithelium (LULs-NDE)
containing p53 mutation, squamous atypia was not found in four LULs-
NDE.
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siodine of Lugol’s solution, normal epithelium of the oesophagus
becomes uniformly greenish brown (Sugimach et al, 1991; Katagiri
et al, 2004). Dysplastic and inflammatory epithelia of the
oesophagus are not stained, as the region showing dysplasia and
oesophagitis has a reduced or no glycogen content (Sugimach et al,
1991). Therefore, these minute lesions that were not identifiable by
conventional endoscopic observation become visible when Lugol’s
solution is used. There is a high possibility that inflammation
having a reduction in glycogen content is related to the initiation
of oesophageal carcinogenesis because no squamous atypia and no
p53 mutations are found in normal Lugol staining areas with
sufficient glycogen content. Squamous atypia would be transitional
lesions from oesophagitis to dysplasia.
Although the prevalence of multiple LULs was low in
oesophageal cancer-free subjects (0.9%), dysplasia occurred
frequently in subjects with multiple LULs (60%). Muto et al
(2002) reported that multiple LULs were found in 27% of head and
neck cancer patients, and secondary ESCCs were found in 72% of
such cancer patients with multiple LULs. They provided essential
information about field cancerisation and malignant potential with
respect to multiple LULs. The field cancerisation phenomena
proposed that multiple squamous cell carcinomas occurred either
simultaneously with the primary lesion (synchronous) or after a
period of time (metachronous) in the oesophagus and the head
and neck region. There is a possibility that widespread epithelial
oncogenic alterations were found in patients with multiple LULs.
In case 2, the same mutation at codon 218 was found in both LUL-
NDE and dysplastic lesion, whereas p53 mutation was not detected
in background normal Lugol staining epithelium. The p53
mutational status, in this case, reflects the phenomena of field
cancerisation, which can be considered as high malignant
potential.
The p53 missense mutations containing a hotspot mutation were
found in LULs-NDE in oesophageal cancer-free individuals with-
out reflux oesophagitis. The finding suggests that LUL-NDE is an
initial lesion for oesophageal carcinogenesis, and that the role of
BCH is less clear for oesophageal carcinogenesis in Japanese
individuals. The characteristic findings of high-risk population of
oesophageal carcinoma were evaluated by genetic analyses,
because it appeared that we emphasise the importance of both
endoscopic detection of LUL-NDE and molecular diagnosis. We
concluded that the understanding of aetiology in human
oesophageal precursor at the molecular level could provide
essential information about the identification of useful biomarkers
for prevention studies.
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